Lv1
41 积分 2020-11-12 加入
A Phase 1b/2 Trial of BNT324/DB-1311 (B7H3 ADC) With BNT327 (PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC)
1个月前
已关闭
Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin
1个月前
已完结
Preclinical Pharmacokinetics of a Novel anti-c-Met Antibody-Drug Conjugate, SHR-A1403, in Rodents and Non-human Primates
1个月前
已完结
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
1个月前
已完结
Selection and analysis of an optimized antiVEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen
2个月前
已完结
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
2个月前
已完结
Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
3个月前
已完结
The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunity
3个月前
已完结
ATG-101 Is a Tetravalent PD-L14-1BB BispecificAntibody That Stimulates Antitumor Immunity throughPD-L1 Blockade and PD-L1–Directed 4-1BB Activatio
4个月前
已完结
皖公网安备34019202002308
